



Corporate Announcement

Neugenesis to present at The Immunotherapeutics and Vaccine Summit

Burlingame, California, August 17, 2009

Debbie Higgins, Director – Vaccine Research & Development at Neugenesis Corporation will be making a presentation at The Immunotherapeutics and Vaccine Summit (ImVacS) to be held in Providence, RI on August 17-19, 2009. ImVacS brings together international vaccine leaders to discuss challenges and current breakthroughs in the world of vaccines. The four vaccine-focused meetings address innovating strategies to meet current health threats, changing technology for vaccine manufacture, top challenges faced during pre-clinical development, and progress underway for adjuvants and novel delivery systems. The Neugenesis presentation will highlight the fungal production platform as a novel technology in the Production & Manufacturing of Vaccines meeting.

About Neugenesis

Neugenesis Corporation is a privately held biotechnology company which has generated a diverse set of technology platforms for the world wide biotechnology and biopharmaceutical industry. In addition to its new position in vaccines, Neugenesis is also involved in development of technology for production of monoclonal antibodies for biodefense. The Company holds strong intellectual property positions in the areas of production of recombinant monoclonal antibodies, cell based gene-directed evolution, and cell based combinatorial biology. Neugenesis is actively seeking partners in the biopharmaceutical industry to rapidly move the technology into the marketplace.

Contact Information

Laurie Fosner
Neugenesis Corporation
863 Mitten Road, Suite C
Burlingame, CA 94101
(650) 689-2220
www.neugenesis.com.

###